The number of people in Africa receiving antiretroviral medications increased from less than 1 million in 2005 to an estimated 7.1 million in 2012, according to a new report from UNAIDS. The report also notes that AIDS-related deaths and new HIV infections have both fallen by about 30% over the past decade.
HIVandHepatitis.com coverage of the 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013) in Amsterdam, April 24-28, 2013.
Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, and prevention and treatment of hepatocellular carcinoma.
For people with chronic hepatitis C who cannot wait for all-oral regimens, interferon-based therapy is still a reality. Researchers at the recent EASL International Liver Congress (EASL 2013) presented promising data showing that several experimental direct-acting antiviral agents (DAAs) can significantly improve response rates without reducing tolerability.
HIVandHepatitis.com coverage of the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), March 3-6, 2013, in Atlanta.
Conference highlights include experimental therapies for HIV and hepatitis C, HIV cure research, aging, HIV-related conditions and treatment complications, HIV treatment as prevention and PrEP, and HIV/HBV and HIV/HCV coinfection.